RXST RxSight, Inc.
Ophthalmic Goods · Nasdaq · SEC CIK 1111485 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.3%
TTM net income YoY-49.3%
TTM EPS YoY-46.6%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—
Margins
Gross margin76.1%
Operating margin-50.4%
Net margin-43.8%
FCF margin15.3%
EBITDA margin-47.5%
Returns
ROE-20.1%
ROA-16.4%
ROIC (approx.)-22.4%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets25.1%
Debt / equity0.00x
Current ratio4.20x
Interest coverage-4,389.57x
Cash quality & payout
Operating cash flow / net income-0.44x
Accruals ratio-23.7%
Payout ratio—
Capex / revenue4.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $24.59M | $33.74M | $30.89M | $32.61M | $30.34M | $33.64M | $37.90M | $40.21M |
| Cost of revenue | $6.49M | $7.86M | $7.39M | $7.34M | $6.11M | $8.45M | $9.57M | $11.43M |
| Gross profit | $18.10M | $25.89M | $23.50M | $25.26M | $24.23M | $25.19M | $28.33M | $28.79M |
| R&D expense | $9.21M | $9.24M | $9.47M | $8.90M | $9.06M | $10.22M | $10.37M | $9.21M |
| SG&A expense | $27.40M | $30.42M | $31.86M | $27.70M | $27.34M | $28.98M | $28.64M | $28.21M |
| Operating income | -$18.52M | -$13.77M | -$17.83M | -$11.34M | -$12.18M | -$14.00M | -$10.67M | -$8.63M |
| Interest expense | $3,000 | $3,000 | $3,000 | $5,000 | $4,000 | $5,000 | $6,000 | $5,000 |
| Pretax income | -$16.20M | -$12.01M | -$15.88M | -$9.15M | -$9.81M | -$11.75M | -$8.17M | -$5.93M |
| Income tax | $28,000 | $88,000 | $6,000 | $5,000 | $10,000 | $32,000 | $18,000 | $12,000 |
| Net income | -$16.22M | -$12.10M | -$15.88M | -$9.15M | -$9.82M | -$11.79M | -$8.19M | -$5.94M |
| EBITDA | -$17.59M | -$12.77M | -$17.00M | -$10.49M | -$11.32M | -$13.22M | -$9.90M | -$8.11M |
| EPS (basic) | -0.39 | -0.29 | -0.38 | — | -0.24 | -0.29 | -0.20 | — |
| EPS (diluted) | -0.39 | -0.29 | -0.38 | — | -0.24 | -0.29 | -0.20 | — |
| Weighted avg. shares (diluted) | 41.71M | 41.49M | 41.31M | — | 40.97M | 40.74M | 40.51M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $66.72M | $13.35M | $17.57M | $19.95M | $30.38M | $41.10M | $28.75M | $17.46M |
| Short-term investments | $187.97M | $195.45M | $200.31M | $208.18M | $197.88M | $187.14M | $201.34M | $220.52M |
| Receivables | $17.00M | $18.52M | $22.44M | $23.38M | $24.15M | $28.06M | $30.96M | $30.05M |
| Inventory | $39.59M | $37.12M | $34.87M | $31.56M | $28.95M | $25.06M | $23.57M | $22.01M |
| Current assets | $314.80M | $327.40M | $279.23M | $287.46M | $283.88M | $283.87M | $288.41M | $293.82M |
| PP&E, net | $14.65M | $14.04M | $13.23M | $13.06M | $13.10M | $13.26M | $12.56M | $12.41M |
| Total assets | $340.42M | $352.70M | $303.99M | $311.81M | $308.53M | $309.01M | $313.04M | $318.56M |
| Current liabilities | $74.95M | $80.44M | $27.38M | $26.25M | $22.29M | $20.38M | $22.74M | $25.88M |
| Total liabilities | $85.51M | $89.36M | $36.70M | $36.13M | $32.56M | $31.00M | $33.73M | $37.33M |
| Shareholders' equity | $254.91M | $263.34M | $267.30M | $275.68M | $275.97M | $278.01M | $279.32M | $281.24M |
| Shares outstanding | 41.93M | 41.59M | 41.38M | 41.24M | 41.08M | 40.91M | 40.59M | 40.43M |
| Cash flow statement | ||||||||
| Operating cash flow | $45.22M | -$9.54M | -$10.89M | -$1.12M | -$1.19M | -$4.38M | -$8.83M | -$4.26M |
| Capital expenditure | $1.17M | $1.96M | $759,000 | $1.14M | $581,000 | $1.54M | $575,000 | $847,000 |
| Free cash flow | $44.04M | -$11.49M | -$11.65M | -$2.25M | -$1.77M | -$5.91M | -$9.41M | -$5.11M |
| Investing cash flow | $7.95M | $4.65M | $8.85M | -$9.61M | -$9.00M | $14.65M | $20.86M | $1.32M |
| Financing cash flow | $195,000 | $662,000 | -$336,000 | $1.06M | -$530,000 | $2.06M | -$735,000 | $2.98M |
| Depreciation & amortization | $929,000 | $999,000 | $834,000 | $851,000 | $854,000 | $785,000 | $776,000 | $515,000 |
| Stock-based compensation | $7.63M | $7.46M | $7.95M | $7.82M | $8.11M | $8.55M | $7.14M | $7.28M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.